# T1 Energy Inc.: financial statements, quarterly

TE · NYSE · CIK 1992243 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/te.md) · [Financials](/companies/te/financials.md) · [Filings](/companies/te/filings.md) · [Insiders](/companies/te/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/te/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001992243-25-000029.md) | [0.0](/filings/0001992243-25-000033.md) | [0.0](/filings/0001992243-25-000040.md) | [2.9 d](/filings/0001992243-26-000007.md) | [53.5](/filings/0001992243-26-000014.md) | [133](/filings/0001992243-26-000022.md) | [211](/filings/0001992243-25-000040.md) | [359 d](/filings/0001992243-26-000007.md) | [178](/filings/0001992243-26-000014.md) | [250](/filings/0001992243-26-000022.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0001992243-25-000029.md) | [0.0](/filings/0001992243-25-000033.md) | [0.0](/filings/0001992243-25-000040.md) | [1.7 d](/filings/0001992243-26-000007.md) | [35.7](/filings/0001992243-26-000014.md) | [100](/filings/0001992243-26-000022.md) | [189](/filings/0001992243-25-000040.md) | [375 d](/filings/0001992243-26-000007.md) | [149](/filings/0001992243-26-000014.md) | [201](/filings/0001992243-26-000022.md) |
| Gross profit | $m | not reported | not reported | [0.0](/filings/0001992243-25-000029.md) | [0.0](/filings/0001992243-25-000033.md) | [0.0](/filings/0001992243-25-000040.md) | [1.2 d](/filings/0001992243-26-000007.md) | [17.8](/filings/0001992243-26-000014.md) | [32.8](/filings/0001992243-26-000022.md) | [21.1](/filings/0001992243-25-000040.md) | [(16.1) d](/filings/0001992243-26-000007.md) | [29.1](/filings/0001992243-26-000014.md) | [49.1](/filings/0001992243-26-000022.md) |
| Research and development | $m | [7.1](/filings/0001992243-24-000157.md) | [10.2 d](/filings/0001992243-24-000066.md) | [11.7](/filings/0001992243-24-000100.md) | [10.5](/filings/0001992243-24-000127.md) | [8.6](/filings/0001992243-24-000157.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | [15.0](/filings/0001992243-25-000029.md) | [13.7](/filings/0001992243-25-000033.md) | [17.4](/filings/0001992243-25-000040.md) | [33.1 d](/filings/0001992243-26-000007.md) | [43.4](/filings/0001992243-26-000014.md) | [62.7](/filings/0001992243-26-000022.md) | [62.7](/filings/0001992243-25-000040.md) | [69.3 d](/filings/0001992243-26-000007.md) | [51.6](/filings/0001992243-26-000014.md) | [71.9](/filings/0001992243-26-000022.md) |
| Operating income | $m | [(35.0)](/filings/0001992243-24-000157.md) | [38.4 d](/filings/0001992243-25-000010.md) | [(15.0)](/filings/0001992243-25-000029.md) | [(13.7)](/filings/0001992243-25-000033.md) | [(17.4)](/filings/0001992243-25-000040.md) | [(32.9) d](/filings/0001992243-26-000007.md) | [(25.6)](/filings/0001992243-26-000014.md) | [(31.4)](/filings/0001992243-26-000022.md) | [(94.7)](/filings/0001992243-25-000040.md) | [(87.0) d](/filings/0001992243-26-000007.md) | [(22.5)](/filings/0001992243-26-000014.md) | [(22.8)](/filings/0001992243-26-000022.md) |
| Income tax | $m | [0.0](/filings/0001992243-24-000157.md) | [0.1 d](/filings/0001992243-25-000010.md) | [0.0](/filings/0001992243-25-000029.md) | [0.0](/filings/0001992243-25-000033.md) | [0.0](/filings/0001992243-25-000040.md) | [(15.8) d](/filings/0001992243-26-000007.md) | [(2.5)](/filings/0001992243-26-000014.md) | [(6.0)](/filings/0001992243-26-000022.md) | [(12.1)](/filings/0001992243-25-000040.md) | [1.2 d](/filings/0001992243-26-000007.md) | [(0.2)](/filings/0001992243-26-000014.md) | [0.8](/filings/0001992243-26-000022.md) |
| Net income | $m | [(9.8)](/filings/0001992243-24-000157.md) | [(24.2) d](/filings/0001992243-24-000066.md) | [(28.5)](/filings/0001992243-24-000100.md) | [(27.0)](/filings/0001992243-24-000127.md) | [(27.5)](/filings/0001992243-24-000157.md) | [(368) d](/filings/0001992243-26-000007.md) | [(16.2)](/filings/0001992243-26-000022.md) | [(31.9)](/filings/0001992243-26-000022.md) | [(131)](/filings/0001992243-25-000040.md) | [(189) d](/filings/0001992243-26-000007.md) | [(20.4)](/filings/0001992243-26-000022.md) | [(43.5)](/filings/0001992243-26-000022.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001992243-24-000157.md) | not reported | [(0.20)](/filings/0001992243-25-000029.md) | [(0.19)](/filings/0001992243-25-000033.md) | [(0.20)](/filings/0001992243-25-000040.md) | not reported | [(0.11)](/filings/0001992243-26-000014.md) | [(0.21)](/filings/0001992243-26-000022.md) | [(0.87)](/filings/0001992243-25-000040.md) | not reported | [(0.08)](/filings/0001992243-26-000014.md) | [(0.16)](/filings/0001992243-26-000022.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001992243-24-000157.md) | not reported | [(0.20)](/filings/0001992243-25-000029.md) | [(0.19)](/filings/0001992243-25-000033.md) | [(0.20)](/filings/0001992243-25-000040.md) | not reported | [(0.11)](/filings/0001992243-26-000014.md) | [(0.21)](/filings/0001992243-26-000022.md) | [(0.87)](/filings/0001992243-25-000040.md) | not reported | [(0.08)](/filings/0001992243-26-000014.md) | [(0.16)](/filings/0001992243-26-000022.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [299](/filings/0001992243-24-000157.md) | [253](/filings/0001992243-25-000010.md) | [250](/filings/0001992243-25-000029.md) | [220](/filings/0001992243-25-000033.md) | [182](/filings/0001992243-25-000040.md) | [72.6](/filings/0001992243-26-000007.md) | [48.9](/filings/0001992243-26-000014.md) | [8.5](/filings/0001992243-26-000022.md) | [34.1](/filings/0001992243-25-000040.md) | [182](/filings/0001992243-26-000022.md) | [46.4](/filings/0001992243-26-000014.md) | [79.1](/filings/0001992243-26-000022.md) |
| Current assets | $m | not reported | [312](/filings/0001992243-25-000010.md) | [268](/filings/0001992243-24-000100.md) | [234](/filings/0001992243-24-000127.md) | [199](/filings/0001992243-24-000157.md) | [572](/filings/0001992243-26-000007.md) | [627](/filings/0001992243-25-000029.md) | [645](/filings/0001992243-25-000033.md) | [695](/filings/0001992243-25-000040.md) | [663](/filings/0001992243-26-000022.md) | [585](/filings/0001992243-26-000014.md) | [751](/filings/0001992243-26-000022.md) |
| Total assets | $m | not reported | [732](/filings/0001992243-25-000010.md) | [670](/filings/0001992243-24-000100.md) | [644](/filings/0001992243-24-000127.md) | [615](/filings/0001992243-24-000157.md) | [1,336](/filings/0001992243-26-000007.md) | [1,432](/filings/0001992243-25-000029.md) | [1,414](/filings/0001992243-25-000033.md) | [1,396](/filings/0001992243-25-000040.md) | [1,372](/filings/0001992243-26-000022.md) | [1,337](/filings/0001992243-26-000014.md) | [1,642](/filings/0001992243-26-000022.md) |
| Current liabilities | $m | not reported | [49.2](/filings/0001992243-25-000010.md) | [40.0](/filings/0001992243-24-000100.md) | [35.4](/filings/0001992243-24-000127.md) | [31.4](/filings/0001992243-24-000157.md) | [410](/filings/0001992243-26-000007.md) | [493](/filings/0001992243-25-000029.md) | [512](/filings/0001992243-25-000033.md) | [616](/filings/0001992243-25-000040.md) | [464](/filings/0001992243-26-000022.md) | [466](/filings/0001992243-26-000014.md) | [577](/filings/0001992243-26-000022.md) |
| Total liabilities | $m | not reported | [97.5](/filings/0001992243-25-000010.md) | [86.6](/filings/0001992243-24-000100.md) | [81.5](/filings/0001992243-24-000127.md) | [76.3](/filings/0001992243-24-000157.md) | [1,099](/filings/0001992243-26-000007.md) | [1,181](/filings/0001992243-25-000029.md) | [1,180](/filings/0001992243-25-000033.md) | [1,240](/filings/0001992243-25-000040.md) | [1,050](/filings/0001992243-26-000022.md) | [1,028](/filings/0001992243-26-000014.md) | [1,367](/filings/0001992243-26-000022.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001992243-25-000010.md) | [508](/filings/0001992243-25-000029.md) | not reported | not reported | [508](/filings/0001992243-26-000007.md) | [488](/filings/0001992243-25-000029.md) | [478](/filings/0001992243-25-000033.md) | [427](/filings/0001992243-25-000040.md) | [344](/filings/0001992243-26-000022.md) | [330](/filings/0001992243-26-000014.md) | [500](/filings/0001992243-26-000022.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001992243-25-000010.md) | [94.4](/filings/0001992243-25-000029.md) | not reported | not reported | [94.4](/filings/0001992243-26-000007.md) | [115](/filings/0001992243-25-000029.md) | [113](/filings/0001992243-25-000033.md) | [120](/filings/0001992243-25-000040.md) | [46.4](/filings/0001992243-26-000022.md) | [48.2](/filings/0001992243-26-000014.md) | [49.6](/filings/0001992243-26-000022.md) |
| Shareholders' equity | $m | [634](/filings/0001992243-24-000157.md) | [633](/filings/0001992243-25-000010.md) | [582](/filings/0001992243-24-000100.md) | [562](/filings/0001992243-24-000127.md) | [539](/filings/0001992243-24-000157.md) | [189](/filings/0001992243-25-000010.md) | [202](/filings/0001992243-26-000022.md) | [184](/filings/0001992243-26-000022.md) | [96.9](/filings/0001992243-25-000040.md) | [250](/filings/0001992243-26-000022.md) | [237](/filings/0001992243-26-000022.md) | [202](/filings/0001992243-26-000022.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.3) d](/filings/0001992243-24-000157.md) | [(34.0) d](/filings/0001992243-25-000010.md) | [(16.2)](/filings/0001992243-25-000029.md) | [(28.0) d](/filings/0001992243-25-000033.md) | [(28.4) d](/filings/0001992243-25-000040.md) | [(30.2) d](/filings/0001992243-26-000007.md) | [(44.8)](/filings/0001992243-26-000014.md) | [33.4 d](/filings/0001992243-26-000022.md) | [63.9 d](/filings/0001992243-25-000040.md) | [43.0 d](/filings/0001992243-26-000007.md) | [(72.9)](/filings/0001992243-26-000014.md) | [(30.1) d](/filings/0001992243-26-000022.md) |
| Capital expenditure | $m | [40.5 d](/filings/0001992243-24-000157.md) | [19.0 d](/filings/0001992243-25-000010.md) | [21.5](/filings/0001992243-25-000029.md) | [7.6 d](/filings/0001992243-25-000033.md) | [5.6 d](/filings/0001992243-25-000040.md) | [16.1 d](/filings/0001992243-26-000007.md) | [29.1](/filings/0001992243-26-000014.md) | [22.8 d](/filings/0001992243-26-000022.md) | [8.9 d](/filings/0001992243-25-000040.md) | [18.0 d](/filings/0001992243-26-000007.md) | [60.7](/filings/0001992243-26-000014.md) | [101 d](/filings/0001992243-26-000022.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [140](/filings/0001992243-24-000100.md) | [140](/filings/0001992243-24-000127.md) | [140](/filings/0001992243-24-000157.md) | [140](/filings/0001992243-25-000029.md) | [140](/filings/0001992243-25-000033.md) | [140](/filings/0001992243-25-000040.md) | [156](/filings/0001992243-26-000014.md) | [156](/filings/0001992243-26-000022.md) | [161](/filings/0001992243-25-000040.md) | [285](/filings/0001992243-26-000014.md) | [280](/filings/0001992243-26-000022.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 294,527,066 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001992243-26-000022.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.